Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best high-return penny stocks to buy right now. On February 5, Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MHR Fund Management Mark Rachesky | 28,967,103 | $79,080,191 | 6.81% | |
| 2. | Invenomic Capital Management Ali Motamed | 11,959,505 | $32,649,449 | +14% | 1.52% |
| 3. | Long Focus Capital Management John B. Helmers | 8,600,000 | $23,478,000 | -6% | 0.62% |
| 4. | Palo Alto Investors William Leland Edwards | 7,116,676 | $19,428,525 | -7% | 2.7% |
| 5. | Millennium Management Israel Englander | 6,585,532 | $17,978,502 | +50% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.84 | 30,000 | $55,200.00 | 30,000 | 2025-06-05 | Filing | |
| $1.74 | 5,600 | $9,743.44 | 206,852 | 2025-05-23 | Filing | |
| $1.69 | 25,000 | $42,250.00 | 374,646 | 2025-05-14 | Filing | |
| $9.15 | 250,000 | $2,287,500.00 | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | $292,800.00 | 54,000 | 2024-02-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | $503,000.00 | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | $178,612.40 | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | $304,799.75 | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | $491,740.20 | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | $117,645.00 | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,518,125 | $80,584,481 | 0% | |
| 2. | 27,207,079 | $74,275,326 | 0% | |
| 3. | 20,161,445 | $55,040,745 | 0% | |
| 4. | 14,277,813 | $38,978,430 | 0% | |
| 5. | 9,191,840 | $25,093,723 | 0% |
News See All
11 Best High Return Penny Stocks to Buy Right Now
Small-cap companies are in the spotlight amid market rotation away from technology heavyweights clobbered by premium valuation.
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc.
11 Best Stocks Under $3 to Buy Right Now
In the stock market, stocks currently trading under $3 per share are typically small-cap stocks, defined as shares of publicly traded companies with a market capitalization between $300 million and $2...
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory
We came across a bullish thesis on Iovance Biotherapeutics, Inc. (IOVA) on r/biotech_stocks by u/DebtFit2132. In this article, we will summarize the bulls’ thesis on IOVA.
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy according to analysts.
10 Best Biotech Penny Stocks to Buy According to Analysts
On December 24, Jared Holz of Mizuho joined 'Power Lunch' on CNBC to talk about how to play biotech moving into 2026.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2025 Earnings Call Transcript November 6, 2025Iovance Biotherapeutics, Inc. beats earnings expectations.
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best healthcare penny stocks to buy now. On September 9, at the H.C.
11 Best Healthcare Penny Stocks to Buy Now
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
Hedge Fund Resource Center Billionaire Hedge Funds
